Cargando…
Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer
Despite recent progress in treating advanced non-small cell lung cancer, clinical intervention in extensive-stage small-cell lung cancer (ES-SCLC) remains stagnant. The purpose of this study was to evaluate the clinical efficacy of cytokine-induced killer (CIK) cells combined with cytotoxic chemothe...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9507303/ https://www.ncbi.nlm.nih.gov/pubmed/36158690 http://dx.doi.org/10.3389/fonc.2022.852885 |
_version_ | 1784796851233357824 |
---|---|
author | Ma, Baozhen Zhou, Yu Shang, Yiman Zhang, Yong Xu, Benling Fu, Xiaomin Guo, Jindong Yang, Yonghao Zhang, Fang Zhou, Mengyuan Huang, Hao Li, Fanghui Lin, Hongwei Zhao, Lingdi Wang, Zibing Gao, Quanli |
author_facet | Ma, Baozhen Zhou, Yu Shang, Yiman Zhang, Yong Xu, Benling Fu, Xiaomin Guo, Jindong Yang, Yonghao Zhang, Fang Zhou, Mengyuan Huang, Hao Li, Fanghui Lin, Hongwei Zhao, Lingdi Wang, Zibing Gao, Quanli |
author_sort | Ma, Baozhen |
collection | PubMed |
description | Despite recent progress in treating advanced non-small cell lung cancer, clinical intervention in extensive-stage small-cell lung cancer (ES-SCLC) remains stagnant. The purpose of this study was to evaluate the clinical efficacy of cytokine-induced killer (CIK) cells combined with cytotoxic chemotherapy, followed by anti-programmed death 1 antibody (sintilimab) maintenance, in ES-SCLC patients. To explore a new method for safe treatment of ES-SCLC patients, thirteen ES-SCLC patients were enrolled between June 2019 and December 2021. All patients received first-line chemotherapy (etoposide plus platinum) combined with CIK cell therapy. Patients who reached a stable disease state or responded well to treatment received sintilimab maintenance treatment. The primary objective of this study was to determine the median overall survival (OS); the secondary objective was to assess the objective response rate (ORR), progression-free survival 1 and 2 (PFS1 was defined as the duration from the signing of informed consent to the date of tumor progression, or death, or the last follow-up. PFS2 was defined as the duration from the first day of sintilimab treatment to the date of tumor progression, death, or the last follow-up.), and adverse reactions. At a 24.1-month follow-up, the median OS was 11.8 (95% confidence interval [CI]: 10.6–13.0) months, median PFS1 was 5.5 (95% CI: 5.0–6.0) months, and the median PFS2 was 2.3 (95% CI: 0.5–4.1) months. The ORR was 76.9% (10/13), the disease control rate was 100% (13/13), and the 20-month survival rate was 41.7%. Eight participants exhibited grade 3 or 4 adverse events after combination therapy. During maintenance treatment with sintilimab, level 3 adverse events occurred in 1 patient (1/9). In conclusion, adding CIK cells to standard chemotherapy regimens, followed by maintenance therapy with sintilimab, may represent a new safe and effective treatment strategy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov (NCT03983759) |
format | Online Article Text |
id | pubmed-9507303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95073032022-09-24 Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer Ma, Baozhen Zhou, Yu Shang, Yiman Zhang, Yong Xu, Benling Fu, Xiaomin Guo, Jindong Yang, Yonghao Zhang, Fang Zhou, Mengyuan Huang, Hao Li, Fanghui Lin, Hongwei Zhao, Lingdi Wang, Zibing Gao, Quanli Front Oncol Oncology Despite recent progress in treating advanced non-small cell lung cancer, clinical intervention in extensive-stage small-cell lung cancer (ES-SCLC) remains stagnant. The purpose of this study was to evaluate the clinical efficacy of cytokine-induced killer (CIK) cells combined with cytotoxic chemotherapy, followed by anti-programmed death 1 antibody (sintilimab) maintenance, in ES-SCLC patients. To explore a new method for safe treatment of ES-SCLC patients, thirteen ES-SCLC patients were enrolled between June 2019 and December 2021. All patients received first-line chemotherapy (etoposide plus platinum) combined with CIK cell therapy. Patients who reached a stable disease state or responded well to treatment received sintilimab maintenance treatment. The primary objective of this study was to determine the median overall survival (OS); the secondary objective was to assess the objective response rate (ORR), progression-free survival 1 and 2 (PFS1 was defined as the duration from the signing of informed consent to the date of tumor progression, or death, or the last follow-up. PFS2 was defined as the duration from the first day of sintilimab treatment to the date of tumor progression, death, or the last follow-up.), and adverse reactions. At a 24.1-month follow-up, the median OS was 11.8 (95% confidence interval [CI]: 10.6–13.0) months, median PFS1 was 5.5 (95% CI: 5.0–6.0) months, and the median PFS2 was 2.3 (95% CI: 0.5–4.1) months. The ORR was 76.9% (10/13), the disease control rate was 100% (13/13), and the 20-month survival rate was 41.7%. Eight participants exhibited grade 3 or 4 adverse events after combination therapy. During maintenance treatment with sintilimab, level 3 adverse events occurred in 1 patient (1/9). In conclusion, adding CIK cells to standard chemotherapy regimens, followed by maintenance therapy with sintilimab, may represent a new safe and effective treatment strategy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov (NCT03983759) Frontiers Media S.A. 2022-09-09 /pmc/articles/PMC9507303/ /pubmed/36158690 http://dx.doi.org/10.3389/fonc.2022.852885 Text en Copyright © 2022 Ma, Zhou, Shang, Zhang, Xu, Fu, Guo, Yang, Zhang, Zhou, Huang, Li, Lin, Zhao, Wang and Gao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Ma, Baozhen Zhou, Yu Shang, Yiman Zhang, Yong Xu, Benling Fu, Xiaomin Guo, Jindong Yang, Yonghao Zhang, Fang Zhou, Mengyuan Huang, Hao Li, Fanghui Lin, Hongwei Zhao, Lingdi Wang, Zibing Gao, Quanli Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer |
title | Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer |
title_full | Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer |
title_fullStr | Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer |
title_full_unstemmed | Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer |
title_short | Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer |
title_sort | sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9507303/ https://www.ncbi.nlm.nih.gov/pubmed/36158690 http://dx.doi.org/10.3389/fonc.2022.852885 |
work_keys_str_mv | AT mabaozhen sintilimabmaintenancetherapypostfirstlinecytokineinducedkillercellspluschemotherapyforextensivestagesmallcelllungcancer AT zhouyu sintilimabmaintenancetherapypostfirstlinecytokineinducedkillercellspluschemotherapyforextensivestagesmallcelllungcancer AT shangyiman sintilimabmaintenancetherapypostfirstlinecytokineinducedkillercellspluschemotherapyforextensivestagesmallcelllungcancer AT zhangyong sintilimabmaintenancetherapypostfirstlinecytokineinducedkillercellspluschemotherapyforextensivestagesmallcelllungcancer AT xubenling sintilimabmaintenancetherapypostfirstlinecytokineinducedkillercellspluschemotherapyforextensivestagesmallcelllungcancer AT fuxiaomin sintilimabmaintenancetherapypostfirstlinecytokineinducedkillercellspluschemotherapyforextensivestagesmallcelllungcancer AT guojindong sintilimabmaintenancetherapypostfirstlinecytokineinducedkillercellspluschemotherapyforextensivestagesmallcelllungcancer AT yangyonghao sintilimabmaintenancetherapypostfirstlinecytokineinducedkillercellspluschemotherapyforextensivestagesmallcelllungcancer AT zhangfang sintilimabmaintenancetherapypostfirstlinecytokineinducedkillercellspluschemotherapyforextensivestagesmallcelllungcancer AT zhoumengyuan sintilimabmaintenancetherapypostfirstlinecytokineinducedkillercellspluschemotherapyforextensivestagesmallcelllungcancer AT huanghao sintilimabmaintenancetherapypostfirstlinecytokineinducedkillercellspluschemotherapyforextensivestagesmallcelllungcancer AT lifanghui sintilimabmaintenancetherapypostfirstlinecytokineinducedkillercellspluschemotherapyforextensivestagesmallcelllungcancer AT linhongwei sintilimabmaintenancetherapypostfirstlinecytokineinducedkillercellspluschemotherapyforextensivestagesmallcelllungcancer AT zhaolingdi sintilimabmaintenancetherapypostfirstlinecytokineinducedkillercellspluschemotherapyforextensivestagesmallcelllungcancer AT wangzibing sintilimabmaintenancetherapypostfirstlinecytokineinducedkillercellspluschemotherapyforextensivestagesmallcelllungcancer AT gaoquanli sintilimabmaintenancetherapypostfirstlinecytokineinducedkillercellspluschemotherapyforextensivestagesmallcelllungcancer |